Although it is a well known fact that hepatocytes are the primary source of plasma proteinase inhibitors, including a,-antichymotrypsin, this protein has also been detected in lung epithelial cells, which may suggest its local production. We have demonstrated that lung-derived epithelial cells are capable of synthesizing high levels of a,-antichymotrypsin.
Introduction
Tissue injury normally results in both a qualitative and quantitative change in the proteins present in human plasma. In man such alterations include an elevation in the levels of C-reactive protein, serum amyloid A, a,-antichymotrypsin (Achy),' a,-proteinase inhibitor, fibrinogen, a-l-acid glycoprotein, haptoglobin and C3 complement, as well as a decrease in albumin and transferrin (1) . These proteins known as acute phase proteins (APP) are predominantly synthesized by the liver. Their production appears to be modulated primarily by cytokines released at the site of injury, although factors generated in tissues distal to the site, such as glucocorticoids, are also involved (1, 2) . Over the past several years, a number of cytokines with hepatocyte stimulating activity have been identified. These include LL-6, IL-1, and TNF-a, of which 11L-6 has been recognized as the principal regulator of most APP genes (1, 2) . More 1 . Abbreviations used in this paper: APP, acute phase proteins; DEX, dexamethasone; ECL, enhanced chemiluminescence; HepG2, human hepatoma; HTB55, human lung adenocarcinoma; OSM, oncostatin M.
recently, oncostatin M (OSM), leukemia inhibitory factor (LIF), IL-il, and cilary neurotrophic factor have also been shown to stimulate APP synthesis in a manner similar to .
The physiologic role of many APP remains unclear, but most of them likely prevent the tissue damage that is associated with inflammation. Such a role has been postulated for Achy, the controlling inhibitor of cathepsin G and other chymotrypsinlike enzymes (3) . Studies of human lung secretions have demonstrated that the concentration of Achy is higher than can be predicted by simple diffusion from blood plasma (4) . This indicates that this inhibitor may be synthesized locally within the lung, possibly by alveolar macrophages that have been shown as one potential source of this inhibitor (5) . The purpose of this study has been to establish whether cells originating from lung epithelium are capable of Achy production under inflammatory conditions. This concept is based on a number of observations, including the fact that (a) Achy is detected in bronchial epithelial tissues (6) and (b) several epithelial cell lines synthesize high levels of Achy (7) (8) (9) (10) . If epithelial cells are capable of Achy synthesis, it seems likely that in the case of lung inflammation mediators generated locally might stimulate Achy production in both hepatocytes and epithelial cells. In the current study normal bronchial epithelial cells as well as HTB55 lung adenocarcinoma cells were examined for expression of Achy. Both type of epithelial cells were found to be strongly responsive to OSM, one of the most potent stimulators of Achy synthesis in cells of hepatic origin.
Methods
Materials. All cytokines used during the course of this study were purified molecules with determined specific activity. Human recombinant IL-l1, ( Determination of protein concentration. The amount of Achy released into the medium was determined by rocket immunoelectrophoresis, as described previously (16) .
Biosynthetic labeling and immunoprecipitation. Confluent monolayers of HTB55 cells were stimulated for 24 h with 50 ng/ml OSM and 10-6 M DEX. The cells were then rinsed and incubated for 3 h in the presence of methionine-free medium containing stimulating factors and 250 kLCi/ml [35S]methionine/cysteine (Tran 35S-label), (ICN Biomedicals, Inc., Costa Mesa, CA). Aliquots of medium were pretreated with preimmune serum and Pansorbin (Calbiochem-Novabiochem, La Jolla, CA), as previously described (13) . The supernatants were than incubated overnight at 40C in 20 mM Tris-HCl, pH 7.5, 140 mM NaCl, 1% Triton X-100, 5 GAPHor in MEM containing either 10% FBS or 50 ng/ml OSM and 100 ng/ml LPS (B). Total cellular RNA isolated at 24 h was subjected to Northern blot analysis. Blots were then hybridized to the Achy probe (upper panels A and B) followed by rehybridization to the GAPDH probe. Samples of cell medium collected at 24 h were subjected to rocket immunoelectrophoresis using antiserum to Achy (A, bottom).
the presence of 100 U/ml IL-l (Fig. 2 B) . The up-regulating effect of IL-1 and DEX was evident within 4-8 h and did not change significantly up to 24 h (Fig. 2 C) . This was confirmed by analysis of the amount of secreted Achy where differences between control and stimulated cells were first observed at 8 h, reaching a maximum at 12 h and remaining constant up to 24 h (data not shown).
We also examined the effect of LPS, a factor known to be a mediator of inflammation. LPS increased Achy mRNA levels at a concentration of 5 jig/ml but was not effective at a 10 times lower concentration.
Stimulation of Achy synthesis in bronchial epithelial cells. Northern blot analysis of RNA extracted from bronchial epithelial cells cultured in bronchial epithelial cell basal medium indicated that Achy transcripts were barely detectable in untreated cells but substantially induced by OSM. To compare the responsiveness of HTB55 and normal bronchial epithelial cells, we also tested the latter cells in the same medium. Since these cells do not grow in MEM, they were first cultured in bronchial epithelial cell basal medium and, after reaching confluency, incubated in MEM. Changing of the medium resulted in an elevation of Achy levels which, however, remained relatively stable after reaching a maximum. As demonstrated in Fig. 3 A, OSM and to a lesser extent IL-1 upregulated Achy synthesis in bronchial epithelial cells, IL-6, however, having no effect. OSM and IL-1 appeared to act additively which was clearly observed at the protein level. LPS in the presence of serum was also capable of stimulating Achy expression, although its effect was less apparent than that of OSM (Fig. 3 B) . As illustrated in Fig. 4 A, maximal cell response was observed at 200 ng/ml OSM, the highest examined concentration, but was also evident at a concentration of 10 ng/ml. The increase in Achy synthesis was clearly noted at 6 h after OSM addition, with maximum stimulation occurring at 24 h (Fig. 4 B) . To determine if upregulation of Achy levels involved transcription or posttranscriptional events, cells were treated with the transcriptional inhibitor actinomycin D and activated by OSM (or not activated in case of control cultures). Fig. 4 previously demonstrated with normal bronchial epithelial cells. This was deemed important in view of the fact that IL-6 and OSM trigger similar biological responses, including up-regulation of Achy in cells of hepatic origin. Fig. 5 shows that OSM alone, or in combination with DEX, significantly stimulated production of Achy, IL-6 alone, again, having no effect (also demonstrated in Fig. 1 ). The effect of OSM was observed either at mRNA (Fig. 5 A) or protein levels (Fig. 5 B) . However, treatment of cells with IL-6 and OSM together, did not increase the effect of OSM when examined at 24 h.
Since the lack of responsiveness to IL-6 might result from the absence of the IL-6 receptor (gp80), we also performed Northern blot analysis of gp8O mRNA levels in HTB55 cells treated with DEX and/or IL-1. These factors were chosen because of (a) their ability to up-regulate gp8O expression (19, 20) After 24 h total cellular RNA was isolated and subjected to Northern blot analysis. Blots were hybridized to the gp8O probe followed by rehybrydization to the GAPDH probe. fested by Achy expression. As demonstrated in Fig. 6 , gp8O was expressed in HTB55 cells following DEX stimulation. However, IL-i was neither capable of increasing gp8O gene expression (Fig. 6 ) nor intensifying the effect of DEX (data not shown). Characterization of Achy produced by HTB55 cells. As shown in Fig. 5 and Table I , the amount of Achy produced by HTB55 and HepG2 cells was surprisingly comparable, both sources having inhibitory activity towards cathepsin G (J. Cichy, unpublished observation). We used condition medium from HTB55 cells to analyze the form of Achy originating from lung epithelium. The presence of a single band in HTB55 supernatants, detected using antibodies against Achy, is demonstrated in Fig. 7 A. This band had a different electrophoretic mobility compared to serum Achy (74 versus 68 kD). While this could be due to a variation in sialic acid content, desialylation of Achy by neuraminidase did not eliminate the differences, although a decrease in the molecular masses of each protein was observed. We then performed N-glycosidase F digestion to remove Asn-linked oligosaccharides. As shown in Fig. 7 BA a partial deglycosylation was obtained, reflected by several bands. These bands probably correspond to Achy with a number of Nglycan chains removed. This is assumed on the basis of previous studies where N-glycosidase F deglycosylation of serum Achy was performed (21) . In accordance with this study five Achy forms were detected, indicating that serum Achy may carry four Asn-linked oligosaccharides. It appears that at least three Nglycosylation sites are occupied in Achy secreted by HTB55 cells (Fig. 7 B) . Apparently, totally deglycosylated Achy corre- (23, 24) , there is much less known about differences in the response to these cytokines. At least two explanations have been suggested. These are (a) differential expression of the private ligand-specific receptors (23) , and (b) the triggering of different signaling pathways (24) . Data presented in this paper provide an interesting model for further investigation of this problem. Regulation of Achy in lung-derived epithelial cells in one respect resembles that found in cells of hepatic origin. In that this inhibitor is under the control of OSM in both cases (Figs. 3 and 5), (26) . However, responsiveness to either IL-I or LPS appears to be specifically directed to epithelial cells. Since both factors are considered to be "alarm molecules" of inflammation, these data suggest that synthesis of Achy in lung epithelial cells may be triggered at early stage of this process.
Achy secreted by HTB55 cells was capable of forming complexes with cathepsin G, which is in agreement with findings by others who also demonstrated the inhibitory activity of epithelial cell-derived Achy (7, 9) . However, a significant difference with respect to molecular size was found between serum Achy and Achy derived from HTB55 cells (Fig. 7) . This most likely resulted from a modified pattern of glycosylation, since the electrophoretic mobility of the polypeptide chain in SDS-PAGE after N-glycanase treatment was similar in both cases. This molecular mass is in accordance with that determined previously for recombinant Achy (14) . However, other modifications can not be excluded, especially since heterogeneity at the amino terminus has also been reported for Achy (27) . Although the physiological significance of this observed variability is unknown, it could provide a tool to establish sources of Achy in lung fluids. Because the respiratory tract is particularly vulnerable to damage by proteolytic enzymes, high levels of Achy and upregulation of its expression by inflammatory cytokines in lung-derived epithelial cells may suggest a contribution by lung epithelium in protecting itself and surrounding tissues from proteolytic attack.
